Key result
Newer ACE inhibitors were associated with lower total median monthly costs ($53.09 vs $59.82; p<0.0009) and higher adherence (66% vs 58%; p<0.0001) compared to older agents in elderly patients.
Why the study?
Do newer ACE inhibitors reduce total cost and improve adherence compared to older ACE inhibitors in elderly hypertensive patients?
Cohort (n=6,176)
Do newer ACE inhibitors reduce total cost and improve adherence compared to older ACE inhibitors in elderly hypertensive patients?
Absolute Event Rate: 53.09% vs 59.82%
p-value: p=<0.0009
Newer ACE inhibitors are associated with lower total monthly costs and higher adherence compared to older ACE inhibitors in elderly hypertensive patients.
No takes yet. Share an insight, caveat, or question.
May support preferring newer ACE inhibitors for lower costs and adherence in elderly hypertension; leaves open need for randomized confirmation.
Small et al. (1997) conducted a cohort in hypertension (n=6,176). Newer ACE inhibitors vs. Older ACE inhibitors was evaluated on Total median cost per month (p=<0.0009). Newer ACE inhibitors were associated with lower total median monthly costs ($53.09 vs $59.82; p<0.0009) and higher adherence (66% vs 58%; p<0.0001) compared to older agents in elderly patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: